
Product Manual


ViraSafe™ miRNA Lentiviral Expression System, Ecotropic

Catalog Number

VPK-220-ECO

1 kit

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

MicroRNAs (miRNAs) are 18–24 nucleotide RNA molecules that regulate the stability or translational efficiency of target mRNAs. These regulatory RNAs function by acting as sequence-specific guides which recruit a large protein complex known as the RNA-induced silencing complex (RISC) to target mRNAs which are subsequently silenced. Diverse functions have been attributed to miRNAs including the regulation of cellular differentiation, proliferation, and apoptosis. Moreover, significant evidence has accumulated implicating a fundamental role for miRNAs in the development of cancer. miRNAs are initially transcribed as long precursor transcripts known as primary microRNAs (pri-miRNAs). Within these transcripts, the mature miRNA sequences are found in ~60–80 nucleotide hairpin structures. Mature miRNAs are generated from pri-miRNAs by sequential processing (Figure 1). Pri-miRNAs are initially recognized in the nucleus by the microprocessor complex which includes as core components the RNase-III enzyme Drosha and its obligate partner DGCR8. This complex excises the hairpin structure containing the mature miRNA sequence. The liberated hairpins, referred to as precursor miRNAs (pre-miRNAs), are recognized by the nuclear export factor exportin 5 which transports them to the cytoplasm. There, the RNase-III enzyme Dicer performs a second cleavage to generate a double-stranded 18–24 nucleotide RNA molecule. The RISC then associates with this RNA duplex and unwinds it. Generally, only one strand is stably incorporated into the RISC; the other is discarded and rapidly degraded. miRNAs guide the RISC to target messages that are subsequently cleaved or translationally silenced.




Figure 1. miRNA Biogenesis and function

Lentivirus vector based on the human immunodeficiency virus-1 (HIV-1) has become a promising vector for gene transfer studies. The advantageous feature of lentivirus vector is the ability of gene transfer and integration into dividing and non-dividing cells. The pseudotyped envelope with vesicular stomatitis virus envelope G (VSV-G) protein broadens the target cell range. Lentiviral vectors have been shown to deliver genes to neurons, lymphocytes and macrophages, cell types that previous retrovirus vectors could not be used. Lentiviral vectors have also proven to be effective in transducing brain, liver, muscle, and retina *in vivo* without toxicity or immune responses. Recently, the lentivirus

system is widely used to integrate siRNA efficiently in a wide variety of cell lines and primary cells both *in vitro* and *in vivo*.

Lentivirus particles are produced from 293T cells through transient transfection of plasmids that encode for the components of the virion (Figure 2). Due to safety concerns regarding the infectious nature of HIV-1, recent lentiviral packaging systems have separated the viral components into 3 or 4 plasmids. However, these systems still present a small chance of generating replication-competent lentivirus upon recombination. In addition, most commercial lentiviral packaging systems provide plasmids containing the viral structure proteins in a premixed formulation, making it nearly impossible to optimize the ratio of the various plasmids for your particular experiment and host cell. Also, most commercial lentivirus transfer vectors contain promoters, antibiotic selection markers and/or reporter genes which may not be optimal or even suitable for your particular expression studies.

Cell Biolabs' ViraSafe™ Lentiviral Expression System provides a much safer method to package lentivirus, while still providing high viral titers. The sequence homology with native HIV-1 has been reduced by 80-90% even compared with commercial third-generation packaging systems. In addition, each plasmid is provided separately rather than in a packaging mixture. This allows you the flexibility to amplify individual plasmids and optimize the ratio of plasmids for your experiment.

Cell Biolabs' pSMPUW-miR-GFP/Puro Lentiviral Expression Vector is designed to clone and express an individual miRNA precursor in its native context while preserving putative hairpin structures to ensure biologically relevant interactions with endogenous processing machinery and regulatory partners, leading to properly cleaved microRNAs. Individual miRNA precursor from any species can be cloned between BamHI and Nhe I sites (Figure 2).

The pSMPUW-miR-GFP/Puro lentiviral expression vector contains the following features:

- **miRNA Processing** – miRNA stem loop precursor in its native context is cloned between BamHI and Nhe I sites. To preserve the putative hairpin structure and proper endogenous processing, miRNA stem loop sequence is flanked by its native intron sequence.
- **EF-1 α Promoter** - ensures a high level of expression in mammalian cells
- **GFP-Puro Fusion Marker** - to monitor cells positive for expression and stable selection with either GFP or puromycin resistance.
- **pUC Origin** - for high copy replication and maintenance of the plasmid in *E. coli*
- **Kanamycin Resistance Gene** - for selection in *E. coli*





Figure 2. Lentivirus Production in 293T Cells

Related Products

1. VPK-107: QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV p24)
2. VPK-112: QuickTiter™ Lentivirus Quantitation Kit
3. VPK-090: ViraBind™ Lentivirus Concentration and Purification Kit
4. LTV-200: ViraDuctin™ Lentivirus Transduction Kit
5. LTV-100: 293LTV Cell Line

Unique Elements of the ViraSafe™ Lentivirus Expression System



Vector Name	Element	Name	Benefits compared to 3 rd Generation System
ELEMENTS ADDED			
Transfer Vector		Central Polypurine Tract	<ul style="list-style-type: none"> Increased gene expression levels
		Hybrid 3' LTR Poly(A)	<ul style="list-style-type: none"> Increased safety: prevents read-through transcription Increased viral titer: vector transcript more stable in packaging cells
		WPRE	<ul style="list-style-type: none"> Increased viral titer
Packaging Vector #1		Codon Wobble	<ul style="list-style-type: none"> Increased safety: reduces sequence homology
		Adenovirus VA	<ul style="list-style-type: none"> Increased viral titer
ELEMENTS REMOVED			
Transfer Vector		Gag sequence	<ul style="list-style-type: none"> Increased safety: reduces sequence homology
		Rev-Responsive Element	<ul style="list-style-type: none"> Increased safety: reduces sequence homology

Kit Components

1. pSMPUW-miR-GFP/Puro Lentiviral Expression Vector (Part No. VPK-220): One 40 μ L vial at 0.25 mg/mL. The plasmid is kanamycin resistant. *Note: Bacterial culture of pSMPUW vector should be done in medium containing **10 μ g/mL** Kanamycin.*
2. pRSV-Rev Packaging Vector (Part No. 320022): One 40 μ L vial at 0.25 mg/mL.
3. pCMV-Eco Envelope Vector (Part No. 320026): One 40 μ L vial at 0.25 mg/mL.
4. pCgpV Packaging Vector (Part No. 320024): One 40 μ L vial at 0.25 mg/mL.
5. pSMPUW-LacZ Control Vector (Part No. 320025): One 40 μ L vial at 0.25 mg/mL containing a nuclear localized LacZ driven by MND retroviral LTR promoter. The plasmid is kanamycin resistant. *Note: Bacterial culture of pSMPUW vector should be done in medium containing **10 μ g/mL** Kanamycin.*

Materials Not Supplied

1. 293T cells: we recommend 293LTV Cell Line (Cat.# LTV-100) for high titer production of lentivirus.
2. Cell Culture Medium
3. Transfection Reagents

Storage

Upon receipt, store all other kit components at -20°C until their expiration dates.

Safety Considerations

Remember that you will be working with samples containing infectious virus. Follow the recommended NIH guidelines for all materials containing BSL-2 organisms. The ViraSafe™ Lentiviral Expression System is designed to minimize the chance of generating replication-competent lentivirus, but precautions should still be taken to avoid direct contact with viral supernatants.

Reverse PCR Primer: tcga-gctagc (NheI)-21 nt

For human let-7a-2 miRNA precursor:

Forward PCR Primer: tcga-ggatcc-gcccaaataaggtgacagcacg

Reverse PCR Primer: tcga-gctagc-aaataccataaaaataatcgta

- 3) PCR the miRNA precursor from genomic DNA and clone into the BamHI/NheI sites of the expression vector.

PCR Product of let-7a-2 precursor: let-7a-2 stem-loop sequence is underlined.

```
1 tcgaggatcc gcccaaatag gtgacagcac gatgaatcat tataagacta acttgtaatt
61 tccctgctta agaaatggta gttttccagc cattgtgact gcatgctccc aggttgaggt
121 agtaggttgt atagtttaga attacatcaa gggagataac tgtacagcct cctagctttc
181 cttgggtctt gcactaaaca acatggtgag aacgatcatg attcctccag gccttttctc
241 cctatgaaag gtaagattgg gtacgattat tttatggtat ttgctagctc ga
```

- 4) Validate the insert by DNA sequencing.

Forward Sequencing Primer: TTTGCACCATTTCTAAAGAAT

Reverse Sequencing Primer: AAACCTCTTACATCAGTTAC

Lentivirus Production

1. One day before transfection, plate sufficient 293T cells or 293LTV cells (Cat. # LTV-100) to achieve 70-80% confluence on the day of transfection.
2. Transfect cells by Calcium Phosphate or other transfection reagents.

Note: We suggest transfecting cells with FuGENE® Transfection Reagent (Roche Applied Science) or Lipofectamine™ Plus (Invitrogen). We recommend the ratio of vectors at 3:1:1:1 (pSMPUW: pCMV-Eco:pRSV-REV:pCgpV).

3. Harvest lentiviral supernatant 36-72 hours after transfection. Supernatant can be harvested 2 or 3 times, every 12 hours. Keep it at 4°C over the collecting period.
4. Pool the collected supernatants, centrifuge 5 minutes at 1500 rpm to remove cell debris and filtrate on 0.22 µm.
5. Supernatants can be used directly or purified/concentrated if needed. For long term storage, store supernatant at -80°C in aliquots.

Post-Packaging Considerations

Packaging your lentivirus is only the first step to ensuring successful expression of your gene. The following steps should be considered prior to infection of your host cell:

1. **Concentration and purification of your lentivirus:** Because of the latent nature of lentivirus, it is imperative that your virus be highly concentrated before infecting your host cell. Also, impurities from your viral supernatant can decrease the efficiency of infection. We recommend

2. **Measure the titer of your lentivirus:** This is an important step to ensure consistent viral transduction into your host cell. However, QPCR or stable clone counting can take as much as 1-2 weeks to perform. Traditional p24 ELISA kits can greatly overestimate your lentiviral titer. Our advanced p24 ELISA, QuickTiter™ Lentivirus Titer Kit (Catalog # VPK-107), uses exclusive technology that eliminates free p24 from your supernatant, giving you much more accurate lentiviral titers. Results are obtained in 6-18 hours.
3. **Use transduction reagents to increase infection efficiency:** Many cells are difficult to infect with lentivirus, and without supplemental reagents transduction efficiencies can be low. Reagents such as Polybrene® can help, but are often insufficient. Cell Biolabs' proprietary reagents in our ViraDuctin™ Lentivirus Transduction Kit (Catalog # LTV-200) form a super-complex with your virus to increase transduction efficiencies by promoting virus and cell interaction.

References

1. microRNA sequences listed in Sanger's miRBase (<http://microrna.sanger.ac.uk/sequences/>).
2. John, B., C. Sander and D. S. Marks (2006) *Methods Mol Biol* **342**: 101-13.
3. Chen, M. et al. (2002). *Nature Genetics* **32(4)**: 670-675.
4. Naldini, L., U. Blomer, P. Gally, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono (1996) *Science* **272**:263-267.
5. Verma, I. M., and N. Somia (1997) *Nature* **389**:239-242.
6. Kahl C. A., Marsh J., Fyffe J., Sanders D. A., and K. Cornetta (2004) *J Virol.* **78**:1421-30.
7. White S. M., Renda M., Nam N. Y., Klimatcheva E., Zhu Y., Fisk J., Halterman M., Rimel B. J., Federoff H., Pandya S., Rosenblatt J. D., and V. Planelles (1999) *J Virol.* **73**:2832-40.
8. Kafri T., van Praag H., Ouyang L., Gage F. H., and I. M. Verma (1999) *J Virol.* **73**:576-84.

Appendix

Vector Features:

- 1084 ~ 1479: EF-1 α Promoter
- 1512 ~ 2002: human β -globin intron
- 1728 ~ 1733: BamHI
- 1744 ~ 1749: NheI
- 2030 ~ 3352: GFP-Puro Fusion (GFP: 2030 ~ 2746; Puro: 2753 ~ 3352)
- 5941 ~ 6756: Kanamycin Resistance Gene (complementary strand)

Plasmid Sequence:

ACTAGTCGGGGTCATTAGTTTCATAGCCCATATATGGAGTTCGCCGCTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACC
GCCAACGACCCCCGCCAATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTTGACGTCAA
TGGGTGGAGTATTTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCA
ATGACGGTAAATGGCCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT
AGTCATCGCTATTACCATGGTGTATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTTGACTCACGGGGATTTCCA
AGTCTCCACCCCAATTGACGTCAATGGGAGTTTTGTTTTTGGCACCAAAATCAACGGGACTTTCCTAAAATGTCTGAACAACTCCG
CCCCATTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCATATAAAGCAGAGCTGGTTTTAGTGAACCGGGTCTCTCT
GGTTAGACCAGATTTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAAGTACTAGAGATCCCTCAGACCCTTTTTAGTCAAGTGTGGAAAAATC
TCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCCTGCTGA
AGCGCGCACGGCAAGAGGCGAGGGCGGCGACTGCAGAGTACGCCAAAAATTTTGGACTAGCGGAGGCTAGAAGGAGAGAGAT
GGGTGCGAGAGCGTCAAGTAAAGCGGGGAAAAATAGCGGCCGCCACAAATTTTAAAAGAAAAGGGGGGATTTGGGGGGTACAG
TGCAGGGGAAAAGAAATAGTAGACATAAATAGCAACAGACATACAAACTAAAGAAATACAAAAACAAATACAAAAATCAAATTT
TTCGGGGGATCTTCGATGCTTCCCGTCCACCACCCCGCCCAACCCGCCCCGACCGGAGCTGAGAGTAAATTCATACAAAAAGGA
CTCGCCCCCTGGGGAATCCCAAGGGACCGTCCGTTTAAACTCCCACTAACCGTAGAACCCAGAGATCGCTGCGTTTTCCCGCCC
CCTCACCCCGCCCGCTCTCGTCACTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTGCCCGTCAAGTGGGCGAGAGCGCAC
ATCGCCACAGTCCCGGAGAAGTTGGGGGGAGGGGTCGGCAATTTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGG
GAAAGTGATGTCGTACTGGCTCCCGCTTTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCCGCGTGAACC
TTCTTTTTCGCAACGGGTTTTGCCGCCAGAACACAGGTACACATATTGACCAAAATCAGGGTAAATTTTGCATTTGTAATTTTAA
AAAATGCTTTCTCTTTTAAATAATCTTTTTTGTATTATCTTATTTCTAATACTTTCCCTAATCTCTTTCTTTAGGGCAATAA
TGATACAAATGTATCATGCCCTTTTGCACCAATCTTAAAGCAATAACAGTGATAAATTTCTGGGTTAAAGGCAATAGCCGATTAGTT
CTCGAGGATCCGACTGAAGTCCGCTAGCTCGAGCTTTTGGAGAATATTTCTGCATATAAAATATTTCTGCATATAAAATTTGTAAC
TGATGTAAGAGTTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCAATCTGCTTTTTATTTTATGGTTGGGATAAAGGCTG
GATTAATCTGAGTCCAAGCTAGGCCCTTTTTGCTAATCATGTTTCATACCTCTTATCTTCCCTCCCACAGCTCCTGGGCAACGTG
CTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGCACGTGAGATCTGAATTTCTGACACACCATGCTGAGCAAGGGCGAGGAG
CTGTTTACCAGGGTGGTGGCCATCTTGGTTCGAGCTGGACGGCGACGTAACCGCCACAAGTTTCAAGCTGTTCCGGCGAGGGCG
AGGGCGATGCCACCTACGGCAAGCTGACCCCTGAAGTTTCACTGACACCACCGGCAAGCTGCCCCGCCCCCGCCACCCCTCGT
GACCACCTGACCTACGGCGTGCAGTCTTCCAGCCGTACCCCGACCATGAAGCAGCACGACTTCTTCAAGTCCGCCATG
CCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTTCGAGG
GCGACACCCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA
CAACTACAACAGCCACAACGCTTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACCTCAAGATCCGCCACAAC
ATCGAGGACGGCAGCGTGCAGCTCGCCGACCCTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCGACA
ACCCTACCTGAGCACCCAGTCCGCCCAGAGCAAGACCCCAACGAGAAGCGGATCACATGGTCTTGGTGGAGTTTCGTGAC
CGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGCCACCATGACCGAGTACAAGCCACGGTGCGCCCTCGCCACC
CGCGACGACGTCCCCAGGGCCGTACGCACCCCTCGCCGCCGCTTCGCCGACTACCCCGCCACGCGCCACACCGTTCGATCCGG
ACCGCCACATCGAGCGGGTACCGAGCTGCAAGAACTCTTCTCACGCGCGTCCGGGCTCGACATCGGCAAGGTGTGGGTCCG
GGACGACGGCGCCCGGTTGGCGGCTGGACCACGCGGAGAGCGTCAAGCGGGGGCGGTGTTCCGCCGAGATCGGCCCGCGC
ATGGCCGAGTTGAGCGTTCCCGGCTGGCCCGCAGCAACAGATGGAAGGCTCCCTGGCGCCGACCCGCCCCAAGGAGCCCG
CTGGTTTTCCCGCCAGTCCGCGTCCGCGCCAGCCAGGGGCTGGGGCAGCGCCGCTGCTGCTCCCGGAGTGGAGTGGGA
GGCGGCCGAGCGCGCCGGGTGCCCGCTTCTTGGAGACCTCCGCGCCCGCAACCTCCCTTCTACGAGCGGCTCGGCTTC
ACCGTACCCGCGACGTGAGTGGCCGAAGGACCGCGCGACCTGGTGCATGACCCGCAAGCCCGTGCCTGAAGCGGCCGCTCG
ACAATCAACCTCTGGATTACAAAAATTTGTGAAAGATTTGACTGGTATTTCTTAACTATGTTGCTCCTTTTTACGCTATGTGGATA
CGCTGCTTTAATGACCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTTCATTTTTCTCTCTTGTATAAAATCCTGGTTGCTG
TCTCTTTATGAGGAGTTGTGGCCGTTGTGAGCAACGTGGCGTGGTGTGCACTGTGTTTGTGCTGACGCAACCCCACTGGTT
GGGCATTTGCCACCCTGTCAGCTCCTTTCCGGGACTTTTCGCTTTTCCCTTCCCTTATTTGCCACGGCGGAACCTCATCGCCG
CTGCCCTGCCCGTGTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCTGGTGTGTTGTCGGGGAAATCATCGTCTTTT

CCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGG
ACCTTCCCTTCCCCTGGCCTGCTGCCGGCTCTGCGGCCCTTCCCGCTTTCGCTTTCGCCCCTCAGACGAGTCCGGATCTCCCT
TTGGGCGCCCTCCCCTTAGTACTGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTTAA
AGAAAAGGGGGGACTGGAAGGGCTAAATCACTCCCAACGAAGACAAGATCCGGAAATTTATTTGTGAAAATTTGTGATGCTAT
TGCTTTTATTTGTAAACCGGTGCAGCTGCTTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCT
CTGGCTAACTAGGGAACCCACTGCTTAAAGCCTCAATAAAGCTTGCCTTGGAGTGTCTCAAGTAGTGTGTGCCCTCTGTTGTG
TGACTCTGGTAACTAGAGATCCCTCAGACCTTTTTAGTCACTGTGGAAAATCTCTAGCATCTAGAGTATGCAAAGCATGCAT
CTCAATTAGTCAAGCAACCAGGTGTGAAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGT
CAGCAACCATAGTCCCCTCAACTCCGCCATCCCCGCCCTAACTCCGCCAGTTCGCCCATTTCTCCGCCCATGGCTG
ACTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCCTCGCCTCTGAGCTATTCAGAAAGTAGTGAGGAGGCTTTTTTTGGA
GGCCTAGGCTAGAGATCATAATCAGCCATACCACATTTTGTAGAGGTTTTTACTTTGCTTTTAAAAAACCTCCCACACCTCCCCCT
GAACCTGAAACATAAAAATGAATGCAATTTGTTGTTGTTAACTTGTTTATTTGCAGCTTATAATGGTTACAAAATAAAGCAATAGC
ATCACAAAATTTACAAAATAAAGCATTTTTTTTTCACTGCATTTCTAGTTGTGGTTTTGTCCAAACTCATCAATGTATCTTATCATG
TCTGCAAGCCGGGCTTTTTTTTTCTTAGGCCCTTCTTCCGCTTCCCTCGCTCACTGACTCGCTGCGCTCGGTCTGGCTGCGG
CGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAA
AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGCTGGCTTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCA
CAAAAATCGACGCTCAAGTCAAGGTGAGGTTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTTCCCTGGAAGCTCCCTC
GTGCGCTCTCCTGTTCCGACCTGCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATA
GCTCAGCTGTAGGTATCTCAGTTCCGGTGTAGGTCGTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCTCAGCCCGA
CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGT
AACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACACGGCTACACTAGAAGAA
CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCAC
CGCTGGTAGCGGTGGTTTTTTTTGTTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTTGATCTTT
TCTACGGGGTCTGACGCTCAGTGGAAACGAAAATCACGTTAAGGGATTTTTGGTCAATGAGATTATCAAAAAGGATCTTCCCT
AGATCCTTTTTAAAATAAAAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAAACTTTGGTCTGACAGTTACCAATGCTT
AATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCCATAGTTGCCTGACTCCTGCGCAGTCCAAAAAAG
GCTCCAAAAGGAGCCTTTAATTTGTATCGGTGGGCCCTTGAAGAACTCATCGAGCATCAATGAAACTGCAATTTATTCATA
TCAGGATTTATCAATACCATATTTTTGAAAAAGCCGTTTTCTGTAATGAAGGAGAAAACTCACCAGGCAGTTCCATAGGATGG
CAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCTCGTCAAAAATAAGGTT
ATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAAATGGCAAAGCTTATGCATTTCTTTCCAGACTTGTTC
ACAGGCCAGCCATTACGCTCGTCATCAAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGAC
GAAATACGCGATCGCTGTTAAAAGGACAAATACAAACAGGAATCGAATGCAACCCGGCGCAGGAACACTGCCAGCGCATCAAC
AATATTTTCCACTGAATCAGGATATTTCTTAATACCTGGAATGCTGTTTTTCCCGGGGATCGCAGTGGTGGTAAACCATGCA
TCATCAGGAGTACGGAATAAAATGCTTGATGGTGGAAAGGCAATAAATCCGCTCAGCCAGTTTAGTCTGACCATCTCATCTG
TAACATCAATGGCAACGCTACCTTTTGCCATGTTTTAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGT
CGCACCTGATTGCCCGACATTTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCCTC
GAGCAAGACGTTTTCCGTTGAATATGGCTCATTAACACCCCTTGTATTACTGTTTTATGTAAGCAGACAGTTTTTATTTGTTTCATG
ATGATATATTTTTTATCTTGTGCAATGTAACATCAGAGATTTTTGAGACACAACGTGGTTTTAAACAAATAGTCAAAAGCCTCCG
GCC

Notice to Purchaser

This product is sold for research and development purposes only and is not to be incorporated into products for resale without written permission from Cell Biolabs. The patented technology is covered by a license from University of Southern California. By the use of this product you accept the terms and conditions of all applicable Limited Use Label Licenses. You may contact our Business Development department at busdev@cellbiolabs.com for information on sublicensing this technology.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

This product is for RESEARCH USE ONLY; not for use in diagnostic procedures.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2009: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.